Aizawl: At least 145 people died of tuberculosis (TB) in Mizoram in 2025, the highest fatalities in six years since 2020, the state health department said.
According to records from the National TB Elimination Programme under the National Health Mission Mizoram, a total of 2,275 people, including 911 females, were diagnosed with the disease during the same year, a slight decrease from the previous year’s (2024) total of 2,291 cases.
Of the 2,275 new cases, 1,900 were detected in government facilities, while the remaining 375 cases were found in private facilities, the report said.
Altogether, 145 people succumbed to TB in 2025, the highest in six years since 2020, the data added.
Although Mizoram experienced fluctuations in new TB cases over the past six years, fatalities have continuously increased since 2020, officials said.
While 31 people died of TB in 2020, the number of fatalities rose to 46 in 2021, 87 in 2022, 119 in 2023, and 136 in 2024, they added.
Of the 2,275 new cases in 2025, 146 people were diagnosed with multi-drug-resistant tuberculosis (MDR-TB), and 267 others were found to be HIV-positive alongside TB, the data said.
Of the newly diagnosed patients, 2,134 were above 14 years of age, and 141 were below 14 years.
Altogether, 84 percent of the patients have been successfully treated, the data added.
Aizawl district recorded the highest number of cases at 1,569, followed by Lunglei district with 155 cases, and Kolasib district, bordering Assam, reported 138 cases during the same year, it said.
Serchhip district reported the least at 52 cases.
Officials also said that more than 100 people have registered to adopt TB patients or donate to them through the online platform “Nikshay” under the Pradhan Mantri TB Mukt Bharat Abhiyan.
The Pradhan Mantri TB Mukt Bharat Abhiyan was launched nationwide by President Droupadi Murmu in September 2022.
It is a community programme aimed at augmenting community involvement to help India meet its commitment to end TB by 2025, ahead of the global target of 2030.
The initiative also provides additional patient support to improve treatment outcomes and leverages Corporate Social Responsibility (CSR) activities.